0.00
price down icon100.00%   -4.97
 
loading
Precedente Chiudi:
$4.97
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$48.77M
Reddito:
$21.73M
Utile/perdita netta:
$-91.17M
Rapporto P/E:
0.00
EPS:
-0.74
Flusso di cassa netto:
$-286.43M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
Value
$0.00
$0.00
Intervallo di 1 settimana:
Value
$0.00
$0.00
Portata 52W:
Value
$0.00
$28.60

Bluebird Bio Inc Stock (BLUE) Company Profile

Name
Nome
Bluebird Bio Inc
Name
Telefono
339-499-9300
Name
Indirizzo
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Name
Dipendente
375
Name
Cinguettio
@bluebirdbio
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
BLUE's Discussions on Twitter

Confronta BLUE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BLUE
Bluebird Bio Inc
0.00 48.77M 21.73M -91.17M -286.43M -0.74
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-24 Aggiornamento JP Morgan Underweight → Neutral
2024-11-15 Downgrade BofA Securities Buy → Neutral
2024-11-15 Downgrade JP Morgan Neutral → Underweight
2024-08-15 Downgrade JP Morgan Overweight → Neutral
2023-12-11 Downgrade HSBC Securities Hold → Reduce
2023-12-08 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2023-10-17 Iniziato Cantor Fitzgerald Neutral
2023-09-06 Iniziato HSBC Securities Buy
2023-07-19 Aggiornamento BofA Securities Neutral → Buy
2023-06-01 Aggiornamento Barclays Equal Weight → Overweight
2023-04-28 Iniziato JP Morgan Overweight
2023-03-07 Iniziato Robert W. Baird Outperform
2022-08-05 Aggiornamento Barclays Underweight → Equal Weight
2022-08-02 Aggiornamento Raymond James Mkt Perform → Outperform
2022-04-06 Downgrade Cowen Outperform → Market Perform
2022-03-07 Downgrade Barclays Equal Weight → Underweight
2021-11-08 Reiterato Barclays Equal Weight
2021-11-08 Reiterato Canaccord Genuity Hold
2021-11-08 Downgrade Goldman Neutral → Sell
2021-11-08 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-11-08 Reiterato RBC Capital Mkts Sector Perform
2021-11-08 Reiterato Wedbush Neutral
2021-11-08 Reiterato Wells Fargo Equal Weight
2021-08-10 Downgrade Canaccord Genuity Buy → Hold
2021-08-10 Downgrade Goldman Buy → Neutral
2021-08-10 Downgrade Wells Fargo Overweight → Equal Weight
2021-08-10 Ripresa William Blair Mkt Perform
2021-08-09 Downgrade SVB Leerink Outperform → Mkt Perform
2021-07-01 Downgrade Berenberg Buy → Hold
2021-03-10 Aggiornamento Mizuho Neutral → Buy
2021-02-17 Downgrade JP Morgan Overweight → Neutral
2021-02-16 Downgrade BofA Securities Buy → Neutral
2021-02-16 Downgrade Wedbush Outperform → Neutral
2021-02-16 Downgrade William Blair Outperform → Mkt Perform
2020-12-09 Downgrade Maxim Group Buy → Hold
2020-11-11 Iniziato Berenberg Buy
2020-11-05 Downgrade BMO Capital Markets Outperform → Market Perform
2020-11-05 Downgrade Barclays Overweight → Equal Weight
2020-11-05 Downgrade Stifel Buy → Hold
2020-11-02 Aggiornamento William Blair Mkt Perform → Outperform
2020-10-20 Iniziato Mizuho Buy
2020-05-13 Iniziato RBC Capital Mkts Outperform
2020-03-27 Aggiornamento Stifel Hold → Buy
2020-02-19 Downgrade Raymond James Outperform → Mkt Perform
2020-02-03 Ripresa BofA/Merrill Buy
2020-02-03 Aggiornamento Evercore ISI In-line → Outperform
2019-12-13 Aggiornamento Oppenheimer Perform → Outperform
2019-11-26 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-11-19 Downgrade Evercore ISI Outperform → In-line
2019-11-04 Aggiornamento Wedbush Neutral → Outperform
2019-10-01 Iniziato Stifel Hold
2019-08-12 Downgrade William Blair Outperform → Mkt Perform
2019-06-18 Aggiornamento Maxim Group Hold → Buy
Mostra tutto

Bluebird Bio Inc Borsa (BLUE) Ultime notizie

pulisher
Jun 18, 2025

Inside the Future of the Gene Therapy for SCID Market: Forecasts, - openPR.com

Jun 18, 2025
pulisher
Jun 12, 2025

Carlyle and SK Capital Complete Acquisition of bluebird bio - orrick.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bluebird bio Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

Bank of America Corp DE Sells 1,358,195 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

As Gene Therapy Endures ‘Cold Winter,’ FDA Leaders Promise Support - BioSpace

Jun 11, 2025
pulisher
Jun 11, 2025

Adrenoleukodystrophy Treatment Market Overview | HSCT, Gene - openPR.com

Jun 11, 2025
pulisher
Jun 07, 2025

Nuveen Asset Management LLC Decreases Stock Position in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

BNP Paribas Financial Markets Decreases Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

bluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK Capital - MSN

Jun 05, 2025
pulisher
Jun 04, 2025

Beta-Thalassemia (B-thal) Market Set to Witness - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

Sickle Cell Treatment Market 2025 | Advances, Drugs, Therapies & - openPR.com

Jun 04, 2025
pulisher
Jun 03, 2025

bluebird bio acquired to scale gene therapy access By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $47,000 Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Deutsche Bank AG Cuts Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Carlyle, SK Capital close deal for bluebird bio, injecting capital for commercial expansion - The Business Journals

Jun 02, 2025
pulisher
Jun 02, 2025

Bluebird Bio (BLUE) Acquired by Carlyle and SK Capital Partners | BLUE Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Carlyle, SK Capital Partners Close Bluebird Bio Acquisition - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

bluebird bio acquired to scale gene therapy access - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital - Business Wire

Jun 02, 2025
pulisher
May 31, 2025

Carlyle, SK Capital Partners disclose expected closing date of bluebird bio deal - MSN

May 31, 2025
pulisher
May 31, 2025

Carlyle and SK Capital to acquire bluebird bio By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 31, 2025

Northern Trust Corp Reduces Holdings in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

May 31, 2025
pulisher
May 30, 2025

Bluebird Bio (BLUE) Acquisition Nears Completion - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Carlyle, SK Capital, Beacon Set To Close Bluebird Bio Acquisition - Nasdaq

May 30, 2025
pulisher
May 30, 2025

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Carlyle and SK Capital to acquire bluebird bio - Investing.com India

May 30, 2025
pulisher
May 30, 2025

Carlyle-Led Group Closes Tender Offer for Bluebird Bio - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer | BLUE Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Carlyle's $5 Per Share Bluebird Bio Takeover Set for June 2 Close After Successful Tender - Stock Titan

May 30, 2025
pulisher
May 29, 2025

Bluebird Bio's Acquisition Deal Offers Shareholders New Cash Option - Finimize

May 29, 2025
pulisher
May 27, 2025

Bluebird Bio Beats Investor Suit Over FDA Cancer Warning - Law360

May 27, 2025
pulisher
May 27, 2025

Bluebird Bio’s SWOT analysis: biotech firm’s stock faces merger crossroads By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Bluebird Bio’s SWOT analysis: biotech firm’s stock faces merger crossroads - Investing.com

May 27, 2025
pulisher
May 27, 2025

Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's

May 27, 2025
pulisher
May 27, 2025

bluebird bio Reminds Stockholders to Act Now to Tender Shares fo - GuruFocus

May 27, 2025
pulisher
May 27, 2025

bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital - BioSpace

May 27, 2025
pulisher
May 27, 2025

Bluebird Beats Investor Lawsuit Over FDA Black Box Warning (1) - Bloomberg Law News

May 27, 2025
pulisher
May 27, 2025

bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus

May 27, 2025
pulisher
May 25, 2025

High Noon For bluebird (NASDAQ:BLUE) - Seeking Alpha

May 25, 2025
pulisher
May 20, 2025

PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stoc - GuruFocus

May 20, 2025
pulisher
May 20, 2025

PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) Price Target at $44.60 - Defense World

May 20, 2025
pulisher
May 19, 2025

Bluebird Beats Patent Case Over Blood Disease Therapies - Law360

May 19, 2025
pulisher
May 19, 2025

Bluebird Wins Patent Fight Over Two High-Priced Gene Therapies - Bloomberg Law News

May 19, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

May 18, 2025

Bluebird Bio Inc Azioni (BLUE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Capitalizzazione:     |  Volume (24 ore):